LifeCycle Pharma Appoints Dr. Jim New, an Internationally Experienced Pharmaceutical Executive, as the President and Chief Executive Officer

Company Announcement no. 34/2008

To: OMX Nordic Exchange Copenhagen	                    Hørsholm, Denmark,
October 17, 2008 


LifeCycle Pharma Appoints Dr. Jim New, an Internationally Experienced
Pharmaceutical Executive, as the President and Chief Executive Officer. 
Hans Christian Teisen Resigns as the Executive Vice President and Chief
Financial Officer 

LifeCycle Pharma A/S (OMX:LCP) has  appointed Dr.  Jim New as the President and
CEO. Dr. New is an internationally recognized senior executive with extensive
experience in global business development within the pharmaceutical industry
and as the CEO of Abrika Pharmaceuticals. 

“We are proud that it has been possible for Life Cycle Pharma to attract an
international management capacity such as Dr. Jim New as the President and CEO
for our organization. LCP has a late-stage product pipeline with two product
candidates approaching clinical phase III, LCP-Tacro and LCP-AtorFen, and Dr.
Jim New's experience and track record matches the needs of LCP”, says Dr. Claus
Braestrup, Chairman of the Board of Directors. 

“LCP has an extraordinarily strong technology platform that has already been
validated in several clinical stage product development candidates and brought
a product on the U.S. market.  I'm really pleased to be joining an organization
like LCP with so much opportunity in their current and future product
pipeline,” says Dr. New. 

Dr. New was cofounder and CEO of Abrika Pharmaceuticals, a specialty pharma
company focused on the development of controlled-release generic drugs.  Before
that, Dr. New worked for over twenty years with Novartis, Pfizer,
GlaxoSmithKline, and Bristol-Myers Squibb. Dr. New's experience includes the
development of new pharmaceutical technologies, business development and the
licensing of technologies and products. Dr. New received his Ph.D. in Medicinal
Chemistry from the State University of New York Buffalo and his MBA from
Columbia Business School. 

 
Furthermore, Life Cycle Pharma announces today, that Hans Christian Teisen has
decided to resign as the Executive Vice President and Chief Financial Officer
of LifeCycle Pharma in order to take a position as partner and CFO of
PricewaterhouseCoopers effective December 1, 2008. Hans Christian Teisen will
assist LCP on ad hoc basis during the transition to the new CEO and CFO. 

 “We regret Hans Christian Teisen's decision to leave LifeCycle Pharma. At the
same time, I would like to thank Hans Christian for his significant
contributions to the Company under the follow on offering, commercial
activities including the agreement with Cowen, establishing professional
administrative functions and being a valued and respected member of the
executive management team. Certainly, we had hoped to draw on Hans Christian's
professional contributions in developing LifeCycle Pharma  much longer, but
respect the private considerations leading to Hans Christian's decision.” says
Dr. Claus Braestrup. 

For more information, please contact:
LifeCycle Pharma A/S			
Dr. Claus Braestrup			
Chairman of the Board			
Phone: +45 4050 8050 			


About LifeCycle Pharma A/S (“LCP”)
LCP is an emerging specialty pharmaceutical company that, through innovative
technologies, is able to rapidly develop a portfolio of differentiated products
to meet the unique needs of key therapeutic markets and patient populations.
This includes products for immunosuppression, specifically organ
transplantation, and to combat certain cardiovascular diseases. By using its
unique and patented delivery technology, MeltDose®, LCP is able to develop
drugs with enhanced absorption and thereby increased bioavailability. LCP has a
cholesterol lowering product, FenoglideTM, currently on the US market and a
diversified near- and medium-term pipeline, including four product candidates
in clinical trials and two in preclinical stages of development. LCP is listed
on the OMX Nordic Exchange Copenhagen under the trading symbol (OMX: LCP). For
further information, please visit www.lcpharma.com.